For type 2 diabetes mellitus. ANDA 77336, held by Sun Pharm Inds (In). Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 77336 (Metformin Hydrochloride), held by Sun Pharm Inds (In), was first approved by FDA on Feb 9, 2006, with 6 approved supplements and 0 published complete response letters.
Metformin hydrochloride extended-release tablets, USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Metformin hydrochloride is a biguanide indicated as an adjunct to diet and exe rcise to i m p rove gl yc e mic cont rol in adults with t ype 2 diabetes m ellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 9, 2006 | Original application | Approved | None posted |
| Metformin Hydrochloride500MG · tablet, extended release;oral | Metformin Hydrochloride | Discontinued |
| Metformin Hydrochloride750MG · tablet, extended release;oral | Metformin Hydrochloride | Discontinued |
| Aug 11, 2026 | Supplement 31Labeling · Standard review | Approved | None posted |
| Mar 1, 2019 | Supplement 15Labeling · Standard review | Approved | None posted |
| Mar 1, 2019 | Supplement 12Labeling · Standard review | Approved | None posted |
| Sep 28, 2015 | Supplement 7Labeling · Standard review | Approved | None posted |
| Nov 19, 2010 | Supplement 4Labeling | Approved | None posted |
| Nov 7, 2007 | Supplement 1Labeling | Approved | None posted |
| Feb 9, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters